Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients
Details
Serval ID
serval:BIB_3A10AEB3C6E9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients
Journal
International Journal of Radiation Oncology, Biology, Physics
ISSN
0360-3016 (Print)
Publication state
Published
Issued date
01/2006
Volume
64
Number
1
Pages
210-7
Notes
Journal Article
Multicenter Study --- Old month value: Jan 1
Multicenter Study --- Old month value: Jan 1
Abstract
PURPOSE: To assess the outcomes and patterns of failure in solitary plasmacytoma (SP). METHODS AND MATERIALS: The data from 258 patients with bone (n = 206) or extramedullary (n = 52) SP without evidence of multiple myeloma (MM) were collected. A histopathologic diagnosis was obtained for all patients. Most (n = 214) of the patients received radiotherapy (RT) alone; 34 received chemotherapy and RT, and 8 surgery alone. The median radiation dose was 40 Gy. The median follow-up was 56 months (range 7-245). RESULTS: The median time to MM development was 21 months (range 2-135), with a 5-year probability of 45%. The 5-year overall survival, disease-free survival, and local control rate was 74%, 50%, and 86%, respectively. On multivariate analyses, the favorable factors were younger age and tumor size <4 cm for survival; younger age, extramedullary localization, and RT for disease-free survival; and small tumor and RT for local control. Bone localization was the only predictor of MM development. No dose-response relationship was found for doses >30 Gy, even for larger tumors. CONCLUSION: Progression to MM remains the main problem. Patients with extramedullary SP had the best outcomes, especially when treated with moderate-dose RT. Chemotherapy and/or novel therapies should be investigated for bone or bulky extramedullary SP.
Keywords
Analysis of Variance
Bone Neoplasms/mortality/pathology/*radiotherapy
Disease Progression
Disease-Free Survival
Female
Humans
Male
Middle Aged
Multiple Myeloma/pathology
Plasmacytoma/mortality/pathology/*radiotherapy
Radiotherapy Dosage
Retrospective Studies
Treatment Outcome
Pubmed
Web of science
Create date
24/01/2008 18:20
Last modification date
20/08/2019 14:29